Renal and Splenic Infarction: Unusual Manifestation of the Antiphospholipid Syndrome

ELIZABETH F DAHER, RAFAEL S.A. LIMA, ANA CRISTINA L. MELO, GERALDO B SILVA JUNIOR

Abstract
Antiphospholipid syndrome is a multisystem disorder characterized by recurrent thromboses in the arterial system, venous system, or both. A 42-year-old man sought treatment reporting two episodes of abdominal pain in the right flank radiating to his back associated with nausea and vomiting fifteen days prior to admission. Abdominal CT with contrast showed left renal atrophy, renal right and splenic infarction. Laboratory tests showed worsening of renal function after CT contrast: serum creatinine 0.6mg/dL to 5.5mg/dL. The complementary investigation showed anti-cardiolipin antibodies (aCL) positive in high titers; antinuclear antibodies, myeloperoxidase-antineutrophil cytoplasmic antibody, anti-nuclear antibody, serology for hepatitis A, B and C, ELISA anti-HIV and VDRL were negative. A diagnosis of renal and splenic infarction due to antiphospholipid syndrome was made and the patient received treatment with subcutaneous heparin followed by warfarin.

Key-words: Antiphospholipid syndrome, renal infarction, splenic infarction

Introduction:
Antiphospholipid syndrome (APS) is an autoimmune disorder characterized by recurrent thromboses in the arterial system, venous system, or both and/or pregnancy losses, in the presence of persistently elevated levels of anticardiolipin antibodies (aCL) and/or evidence of circulating lupus anticoagulant (LA). The kidney is a major target organ in patients with the APS. The renal manifestations may result from thrombosis occurring at any location within the renal vasculature, including the renal artery trunk or branches, intraparenchymal arteries and arterioles, glomerular capillaries, and the renal veins. We report the case of renal and splenic infarction due to antiphospholipid syndrome.

Case report:
A 42-year-old man sought treatment reporting two episodes of abdominal pain in the right flank radiating to his back associated with nausea and vomiting fifteen days prior to admission. Laboratory tests showed serum creatinine: 0.6mg/dL and urea: 30mg/dL. Chest and abdominal CT with contrast showed left renal atrophy, renal right and splenic infarction. After CT contrast, new laboratory tests showed serum creatinine: 5.5mg/dL and urea: 124mg/dL. Urinalysis revealed 1+ protein, 2+ white blood cells and 4+ red blood cells. The complementary investigation showed anti-cardiolipin antibodies (aCL) positive in high titers; antinuclear antibodies (ANA), myeloperoxidase-antineutrophil cytoplasmic antibody (c-ANCA) and anti-nuclear antibody (ANA) were negative. The serology for hepatitis A, B and C negative; ELISA anti-HIV and VDRL were also negative. The urinary protein excretion was 1.44g/24h and creatinine clearance was 39mL/min/1.73m². A diagnosis of renal and splenic infarction due to antiphospholipid syndrome was made and the patient received treatment with subcutaneous heparin followed by warfarin.

Correspondence: Geraldo B Silva Junior, Department of Internal Medicine, Federal University of Ceará, Fortaleza, Ceará, Brazil. E-mail: geraldobezerrajr@yahoo.com.br
Discussion:
The antiphospholipid syndrome (APS) was first described by Hughes in the 1980s as a disorder of hypercoagulability in association with antiphospholipid antibodies.\(^1\) APS may occur, though less frequently, in the absence of associated autoimmune disease, the so-called primary APS. The diagnosis of APS is made when the patient fulfils at least one clinical (vascular thrombosis or pregnancy morbidity) and one laboratory [LA, aCL and/or anti-β2-glycoprotein-1 (anti-α2GP1) antibodies] criterion.\(^2\)

Arterial thromboses are less common than venous thromboses and occur in a variety of settings in patients with primary APS. Patients with arterial thrombosis most commonly present with transient ischemic attack or stroke (50%) or myocardial infarction (23%).\(^3\) The renal manifestations of APS thus may include renal artery stenosis (RAS) and/or renovascular hypertension, renal infarction, APS nephropathy (APSN), renal vein thrombosis, and increased allograft vascular thrombosis.\(^4\) All vascular structures of the kidney may be affected, leading to diverse clinical consequences including severe hypertension, proteinuria, hematuria, nephrotic syndrome, and renal failure. In some instances end stage renal disease (ESRD) may occur.\(^5\)

Conflict of Interest: None.

References: